IDXG +44% on announcing to cover Interpace's ThyraMIR with UnitedHealthcare.
GNC +19% on Q1 earnings.
FNJN +12% on announcing Q1 earnings.
BIOC +9% on awarding Japanese Patent No. 6081434 entitled devices and methods of cell capture and analysis.
CLRB +8% on receiving the Japanese Patent Office has granted a method of use patent for two of the company’s phospholipid drug conjugates (PDCs), CLR 131, the company’s lead compound, and CLR 125.
XOMA +9% on announcing positive data from pre-clinical studies investigating the activity of its anti-PTH1R antagonist monoclonal antibody.
CAB +8% .
[[IDXG]] +44% on announcing to cover Interpace's ThyraMIR with UnitedHealthcare. [[GNC]] +19% on Q1 earnings. [[FNJN]] +12% on announcing Q1 earnings. [[BI
IDXG +44% on announcing to cover Interpace's ThyraMIR with UnitedHealthcare GNC +19% on Q1 earnings FNJN +12% on announcing Q1 earnings BIOC +9% on awarding Japanese Patent No. 6081434 entitled devices and methods of cell capture and analysis CLRB +8% on receiving the Japanese Patent Office has granted a method of use patent for two of the company’s phospholipid drug conjugates PDCs CLR 131 the company’s lead compound and CLR 125 XOMA +9% on announcing positive data from pre-clinical studies investigating the activity of its anti-PTH1R antagonist monoclonal antibody CAB +8%